paastoinsuliinia

Paastoinsuliinia is the Finnish term for fasting insulin, the level of insulin present in the bloodstream after a period of overnight fasting, typically 8–12 hours. It is a key biomarker in evaluating insulin secretion and resistance, and is used in both clinical and research settings. The measurement is usually performed using venous blood samples obtained in the morning, before breakfast, and is quantified with immunoassays such as ELISA or chemiluminescent immunoassays.

In healthy individuals, fasting insulin ranges from approximately 3 to 20 μU/mL, though reference ranges can vary across laboratories due to assay differences. Elevated fasting insulin levels are often indicative of insulin resistance, a hallmark of conditions such as metabolic syndrome, type 2 diabetes mellitus, and polycystic ovary syndrome. Conversely, low fasting insulin may suggest impaired beta‑cell function, as seen in advanced type 1 diabetes or certain forms of monogenic diabetes.

Paastoinsuliinia values are commonly combined with fasting glucose levels to calculate indices of insulin sensitivity, such as the Homeostatic Model Assessment of Insulin Resistance (HOMA‑IR). HOMA‑IR is computed by multiplying fasting insulin (μU/mL) by fasting glucose (mmol/L) and dividing by 22.5. Higher HOMA‑IR values denote greater insulin resistance.

Clinicians also consider fasting insulin when diagnosing insulinoma, a rare tumor that produces excess insulin. In this context, paradoxical rises in insulin despite hypoglycemia can alert to an insulinoma.

Research studies have used paastoinsuliinia to examine the effects of lifestyle interventions, such as diet and exercise, on insulin sensitivity. Interventions that improve insulin sensitivity typically lower fasting insulin concentrations.

In summary, paastoinsuliinia is a widely used laboratory marker that provides insight into glucose homeostasis, insulin dynamics, and metabolic health.